Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects

British Journal of Clinical Pharmacology

Volumn 65, Issue SUPPL. 1, 2008, Pages 68-75

  Davis, John D ^a   Hackman, Frances ^a   Layton, Gary ^a   Higgins, Tracy ^a   Sudworth, David ^a   Weissgerber, Georges ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

CCR5 inhibitor; Maraviroc; Moxifloxacin; Pharmacokinetics; QTcF; QTcI; Safety

Indexed keywords

MARAVIROC; MOXIFLOXACIN; PLACEBO;

ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; ELECTROCARDIOGRAM; EXERCISE; FEMALE; HEADACHE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; MIXED EFFECTS MODELLING APPROACH; NAUSEA; NORMAL HUMAN; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL; SINGLE DRUG DOSE; STATISTICAL MODEL;

ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CYCLOHEXANES; ELECTROCARDIOGRAPHY; EPIDEMIOLOGIC METHODS; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; QUINOLINES; RECEPTORS, CCR5; TRIAZOLES;

EID: 40549135640     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03138.x     Document Type: Article

References (23)

1. Crumb W, Cavero II. QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. Pharm Sci Technol Today 1999 2 : 270 80.
2. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004 350 : 1013 22.
3. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002 287 : 2215 20.
4. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991 83 : 1888 94.
5. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993 270 : 2590 7.
6. Committee for Proprietary Medicinal Products. Points to Consider: the Assessment of the Potential for QT Interval Prolongation by Non-cardiovascular Medicinal Products. Report no. CPMP/986/96. London, 1997.
7. Dessertenne F. [Ventricular tachycardia with 2 variable opposing foci]. Arch Mal Coeur Vaiss 1966 59 : 263 72.
8. Schwartz PJ, Periti M, Malliani A. The long Q-T syndrome. Am Heart J 1975 89 : 378 90.
9. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995 80 : 795 803.
10. Drici MD, Burklow TR, Haridasse V, Glazer RI, Woosley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996 94 : 1471 4.
11. Pham TV, Sosunov EA, Gainullin RZ, Danilo P Rosen MR. Impact of sex and gonadal steroids on prolongation of ventricular repolarization and arrhythmias induced by I (K)-blocking drugs. Circulation 2001 103 : 2207 12.
12. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005 49 : 4721 32.
13. Mansfield RW, Brunton NS, Sutton MR, Leishman D. Pre-clinical assessment of the potential of UK-427,857, a CCR5 antagonist, to effect cardiac QT intervals. In : 15th International AIDS Conference. 2004 July 11-16; Bangkok, Thailand; 2004.
14. Abel S, van der Ryst E, Rosario MC, Ridgway CE, Medhurst CG, Taylor-Worth RJ, Muirhead GJ. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Brit J Clin Pharm 2008 65 (Suppl. 1 5 18.
15. Shah A, Hajian G. A maximum likelihood approach for estimating the QT correction factor using mixed effects model. Stat Med 2003 22 : 1901 9.
16. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920 7 : 353.
17. Fredericia LS. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med Scand 1920 52 : 469.
18. Darpo B, Agin M, Kazierad DJ, Layton G, Muirhead G, Gray P, Jorkasky DK. Man versus machine: is there an optimal method for QT measurements in thorough QT studies? J Clin Pharmacol 2006 46 : 598 612.
19. Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol 2006 46 : 498 507.
20. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Prog Cardiovasc Dis 2001 43 (5 Suppl. 1 1 45.
21. Demolis JL, Kubitza D, Tenneze L, Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000 68 : 658 66.
22. Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003 73 : 292 303.
23. Wu Y, Anderson ME. Reduced repolarization reserve in ventricular myocytes from female mice. Cardiovasc Res 2002 53 : 763 9.